Summary
Systemic administration of MPTP to experimental animals induces neurodegeneration of dopaminergic neurons in the central nervous system. MPTP crosses the blood-brain barrier where it is taken up by astrocytes and converted to MPP+ by monamine oxidase-B (MAO-B). Subsequently, MPP+ is selectively taken up by dopaminergic neurons upon which it exerts intracellular neurotoxic effects. Systemic administration of the selective MAO-B inhibitor deprenyl prevents the conversion of MPTP to MPP+ and by this mechanism is able to protect against MPTP neurotoxicity. Deprenyl has also been reported to exert neuroprotective effects that are independent of its MAO-B inhibitory properties, but since MPP+ itself does not cross the blood-brain barrier it is difficult to directly study the MAO-B independentin vivo effects of MPP+ itself. One approach is to use organotypic tissue cultures of the canine substantia nigra (CSN) which permit administration of precise concentrations of pharmacological agents directly to mature, well-developed and metabolically active dopaminergic neurons. These neurons as well as other components of the cultures exhibit morphological and biochemical characteristics identical to theirin vivo counterparts. This study was undertaken to evaluate the neuroprotective effects of deprenyl in MPP+-treated cultures by measuring changes in the levels of HVA as an indicator of dopamine release and metabolism by dopaminergic neurons and to correlate this indication of dopaminergic function with morphological evidence of survival or loss of dopaminergic neurons in mature CSN cultures. Mature CSN cultures, at 44 days in vitro (DIV), were exposed to either MPP+ alone, deprenyl alone or simultaneously to both deprenyl and MPP+ or to MPP+ following 4 day pretreatment with deprenyl. Exposure to MPP+ alone caused significant reduction in HVA levels, evidence of widespread injury and ultimate disappearance of large neurons in the cultures. These effects were attenuated by simultaneous exposure to MPP+ and deprenyl and the destructive effects of MPP+ appeared to be prevented by pretreatment with deprenyl. Thus the neuroprotective effects of deprenyl on MPP+-induced reduction of HVA levels in living cultures appears similar to the effects of deprenyl on dopamine levels and tyrosine hydroxylase activity reported by others in cultures previously exposed to deprenyl and MPP+. These studies also confirm that the neuroprotective effects of deprenyl against MPP+ in dopaminergic neurons are, at least in part, independent of deprenyl's inhibition of MAO-B.
Similar content being viewed by others
References
Adeyemo OM, Youdim MBH, Markey SP, Markey CJ, Pollard HB (1993) L-deprenyl confers specific protection against MPTP-induced Parkinson's disease-like movement disorder in the goldfish. Eur J Pharmacol 240: 185–193
Ansari KS, Yu PH, Kruck TPA, Tatton WG (1993) Rescue of axotomized immature rat facial motoneurons by R(−)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 13: 4042–4053
Birkmayer W, Knoll J, Riederer P, Youdim MB (1983) (−)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease. Mod Probl Pharmacopsychiat 19: 170–176
Birkmayer W, Knoll J, Riederer P, Youdim MB (1985) Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm 64: 113–127
Buys YM, Trope GE, Tatton WG (1995) (−)-Deprenyl increase the survival of rat retinal ganglion cells after optic nerve crush. Curr Eye Res 14: 119–126
Chiueh CC, Huang S-J, Murphy OL (1992) Enhanced hydroxyl radical generation by 2-methyl analog of MPTP: suppression by clorgyline and deprenyl. Synapse 11: 346–348
Christie-Pope BC, Burns RS, Whetsell WO (1989) Ultrastructural alterations induced by 1-methyl-4-phenylpyridinium (MPP+) in canine substantia nigra and rat mesencephalon in vitro. Exp Neurol 104: 235–240
Iwasaki Y, Ikeda K, Shiojima T, Kobayashi T, Tagaya N, Kinoshita M (1994) Deprenyl enhances neurite outgrowth in cultured rat spinal ventral horn neurons. J Neurol Sci 125: 11–13
Koutsilieri E, O'Callaghan JFX, Chen T-S, Riederer P, Rausch W-D (1994) Selegiline enhances survival and neurite outgrowth of MPP+-treated dopaminergis neurons. Eur J Pharmacol Mol Pharmacol Sect 269: R3-R4
Koutsilieri E, Chen T-S, Rausch W-D, Riederer P (1996) Selegiline is immunoprotective in primary brain cultures treated with 1-methyl-4-pyridinium. Eur J Pharmacol 306: 181–186
LeWitt PA (1991) Deprenyl's effect at slowing progression of Parkinsonism disability: the Parkinson Study Group. Department of Neurology, Wayne State University School of Medicine, Detroit, MI
Myllyla VV, Sotaniemi KA, Vuorinen JA, Heinonen EH (1991) Selegiline as a primary treatment of Parkinson's disease. Acta Neurol Scand [Suppl] 136: 70–72
Mytilineou C, Cohen G (1985) Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-pyridinium ion. J Neurochem 45: 1951–1953
Nicklas WJ, Vyos I, Heikkila RE (1985) Inhibition of NADH-linked oxidation in brain mitochondria by MPP+, a metabolite of the neurotoxin MPTP. Life Sci 36: 2503–2508
Oh C, Murray B, Bhattacharya N, Holland D, Tatton WG (1994) (−)-Deprenyl alters the survival of adult murine facial motoneurons after axotomy: increases in vulnerable C57BL strain but decreases in motor neurodegeneration mutants. J Neurosci Res 38: 64–74
Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321: 1363–1371
Reniuk NA, Henderson JT, Tatton WG, Doder JC (1994) Increased CNTF gene expression in process-bearing astroyctes following injury is augmented by R(+)-deprenyl. J Neurosci Res 37: 278–286
Salo PT, Tatton WG (1992) Deprenyl reduces the death of motoneurons caused by axotomy. J Neurosci Res 31: 394–400
Schmidt DE, Lynn JC, Whetsell WO (1993) Attenuation of 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity by deprenyl in organotypic cultures of canine substantia nigra. Neurosci Abstr 19: 1680
Sziraki I, Kardos M, Patthy M, Patfalusi M, Gaal J, Solti M, Kollar E, Singer J (1994) Amphetamine-metabolites of deprenyl involved in protection against neurotoxicity induced by MPTP and 2′-methyl-MPTP. J Neural Transm [Suppl] 41: 207–210
Tetrud JW, Langston JW (1989) The effect of deprenyl on the natural history of Parkinson's disease. Science 245: 519–522
Tipton KF, Singer TP (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 61: 1191–1206
Vezina P, Mohr E, Grimes D (1992) Deprenyl in Parkinson's disease: mechanisms, neuroprotective effect, indications and adverse effects. Can J Neurol Sci 19: 142–146
Whetsell WO, Mytileneou C, Shen J, Yahr MD (1981) The development of the dog nigrostriatal system in organotypic culture. J Neural Transm 52: 149–161
Wu R-M, Chiueh CC, Pert A, Murphy DL (1993) Apparent antioxidant effect of 1-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo. Eur J Pharmacol 243: 241–247
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schmidt, D.E., Ebert, M.H., Lynn, J.C. et al. Attenuation of 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity by deprenyl in organotypic canine substantia nigra cultures. J. Neural Transmission 104, 875–885 (1997). https://doi.org/10.1007/BF01285555
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01285555